NasdaqGM:ALVOBiotechs
Alvotech (ALVO) TTM Profitability Challenged By Q4 US$108.5 Million Net Loss
FY 2025 earnings snapshot for Alvotech (NasdaqGM:ALVO)
Alvotech (NasdaqGM:ALVO) closed FY 2025 with Q4 revenue of US$168.9 million and a basic EPS loss of US$0.44, as net income excluding extra items came in at a loss of US$108.5 million. The company has seen quarterly revenue range from US$102.99 million in Q3 2024 to US$173.3 million in Q2 2025, while basic EPS has swung between a loss of US$0.23 in Q4 2024 and a profit of US$0.39 in Q1 2025. This sets up a year where the trailing twelve...